Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction

Cardiovascular toxicity of PI3Kα inhibitors

(2020) Chandu Sadasivan et al.   CLINICAL SCIENCE

Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer

(2019) Angela Esposito et al.   JAMA Oncology

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

(2019) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

(2019) Umberto Campia et al.   CIRCULATION

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Disease and Cancer: Is There Increasing Overlap?

(2019) Logan Vincent et al.   Current Oncology Reports

PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

(2019) Brent A. McLean et al.   Journal of the American Heart Association

Inhibition of PI3Kinase-α is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts

(2019) Pavel Zhabyeyev et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs

(2019) Wang Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities

(2019) Jie Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Failing Heart Stimulates Tumor Growth by Circulating Factors

(2018) Wouter C. Meijers et al.   CIRCULATION

Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic AneurysmNovelty and Significance

(2018) Mengcheng Shen et al.   CIRCULATION RESEARCH

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

The PI3K/AKT pathway in obesity and type 2 diabetes

(2018) Xingjun Huang et al.   International Journal of Biological Sciences

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

(2018) Quitterie Venot et al.   NATURE

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders

(2018) Ralitsa R. Madsen et al.   TRENDS IN MOLECULAR MEDICINE

A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors

(2018) Yuichi Ando et al.   CANCER SCIENCE

Endothelial and cardiomyocyte PI3Kβ divergently regulate cardiac remodelling in response to ischaemic injury

(2018) Xueyi Chen et al.   CARDIOVASCULAR RESEARCH

PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease

(2018) Vaibhav B. Patel et al.   Nature Communications

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

(2018) Dejan Juric et al.   JAMA Oncology

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Mohsen Naghavi et al.   LANCET

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

(2017) Aviram Mizrachi et al.   Nature Communications

Relation of Muscle Mass and Fat Mass to Cardiovascular Disease Mortality

(2016) Preethi Srikanthan et al.   AMERICAN JOURNAL OF CARDIOLOGY

Mesenchymal Stem Cells with eNOS Over-Expression Enhance Cardiac Repair in Rats with Myocardial Infarction

(2016) Leilei Chen et al.   CARDIOVASCULAR DRUGS AND THERAPY

Shared Risk Factors in Cardiovascular Disease and Cancer

(2016) Ryan J. Koene et al.   CIRCULATION

Cardio-Oncology

(2016) Carrie G. Lenneman et al.   CIRCULATION RESEARCH

The Biological Basis for Cardiac Repair After Myocardial Infarction

(2016) Sumanth D. Prabhu et al.   CIRCULATION RESEARCH

Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer

(2016) Tal Hasin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart

(2015) Brent A. McLean et al.   CARDIOVASCULAR RESEARCH

Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population

(2014) J. B. Nielsen et al.   EUROPEAN HEART JOURNAL

BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

(2014) Bérengère Gobin et al.   INTERNATIONAL JOURNAL OF CANCER

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

(2013) Esther Castellano et al.   CANCER CELL

Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues

(2013) Wang Wang et al.   Journal of the American Heart Association

Exercise training and PI3Kα-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling

(2012) Kai-Chien Yang et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Enhanced recovery from ischemia–reperfusion injury in PI3Kα dominant negative hearts: Investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling

(2012) Brent A. McLean et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure

(2011) Kai-Chien Yang et al.   CARDIOVASCULAR RESEARCH

Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden

(2011) Bengt Zöller et al.   EUROPEAN JOURNAL OF CANCER

Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib

(2011) Christopher J. Richards et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

The p110  isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 

(2008) J. Guillermet-Guibert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA